Louisiana State University

LSU Digital Commons
LSU Master's Theses

Graduate School

2008

Transcriptional control of the adiponectin gene by STAT5A
Joel Maier
Louisiana State University and Agricultural and Mechanical College

Follow this and additional works at: https://digitalcommons.lsu.edu/gradschool_theses

Recommended Citation
Maier, Joel, "Transcriptional control of the adiponectin gene by STAT5A" (2008). LSU Master's Theses.
3180.
https://digitalcommons.lsu.edu/gradschool_theses/3180

This Thesis is brought to you for free and open access by the Graduate School at LSU Digital Commons. It has
been accepted for inclusion in LSU Master's Theses by an authorized graduate school editor of LSU Digital
Commons. For more information, please contact gradetd@lsu.edu.

TRANSCRIPTIONAL CONTROL OF THE ADIPONECTIN
GENE BY STAT5A

A Thesis
Submitted to the Graduate Faculty of the
Louisiana State University and
Agricultural and Mechanical College
in partial fulfillment of the
requirements for the degree of
Master of Science
in
The Department of Biochemistry

by
Joel Elisha Maier
B.S., Louisiana State University, 2005
December, 2008

ACKNOWLEDGMENTS
The author would like to thank God for all of his blessings. The author would also
like to thank his committee members for their time.
Special thanks go to his friends and family for supporting him throughout his time
in graduate school. The author also sincerely appreciates the members of his lab for their
friendship and support.

ii

TABLE OF CONTENTS
ACKNOWLEDGMENTS………………………………………………………………...ii
LIST OF TABLES………………………………………………………………………...v
ABSTRACT……………………………………………………………………………vii
CHAPTER 1. INTRODUCTION………………………………………………………....1
1.1
Metabolic Syndrome and the Study of Adipocytes……………………….1
1.2
Adipocyte Cell Lines as a Model System…………………………………2
1.3
JAK/STAT Signaling……………………………………………………...3
1.4
STAT 5A and 5B………………………………………………………….3
1.5
Prolactin and Growth Hormone…………………………………………...5
1.6
Regulation of the JAK/STAT Pathway……………………………………7
1.7
Genes Regulated by STAT5 in Adipocytes……………………………….8
1.8
Protein Interactions with STAT5………………………………………….8
1.9
Adiponectin………………………………………………………………..9
1.10 Adiponectin Receptors …………………………………………………..10
1.11 Actions of Adiponectin ………………………………………………….11
1.12 Single Nucleotide Polymorphisms of the Adiponectin Gene …………...12
1.13 Transcriptional Control of Adiponectin.…………………………………13
CHAPTER 2. MATERIALS AND METHODS………………………………………...18
2.1
Materials…………………………………………………………………18
2.2
Cell Culture………………………………………………………………18
2.3
Preparation of Nuclear and Cytosolic Extracts…………………………..18
2.4
Preparation of Whole Cell Extracts……………………………………..19
2.5
Western Blotting…………………………………………………………20
2.6
Electrophoretic Mobility Shift Assay (EMSA)…………………………..20
2.7
Plasmid Construction…………………………………………………….21
2.8
Transformation and Plasmid Preparation………………………………...22
2.9
Transfections and Luciferase Assays…………………………………….23
CHAPTER 3. RESULTS………………………………………………………………...25
3.1
Prolactin Treatment rResults in a Time Dependent Decrease
in Adiponectin Expression in 3T3-L1 Adipocytes………………………25
3.2
Prolactin Treatment Induces STAT5 Binding of the Murine Adiponectin
Promoter in Vitro ………………………………………………………..26
3.3
Luciferase Assay…………………………………………………………31
CHAPTER 4. DISCUSSION…………………………………………………………….32
4.1
Summary…………………………………………………………………32
4.2
Possible Mechanisms of Adiponectin Regulation ………………………33
4.3
Potential Impact of STAT5 Regulation of Adiponectin…………………34

iii

BIBLIOGRAPHY………………………………………………………………………..36
VITA……………………………………………………………………………………..50

iv

LIST OF TABLES
1. Comparison of Promoter Response Elements……………………………………16
2. Primary and Complementary DNA Strands Used in
EMSAs…………………………………………………………………………...22
3. PCR Primers used in this Study………………………………………………….23
4. PRL Responsive Sequences……………………………………………………...26
5. Human and Murine Adiponectin Promoter STAT5 Binding Sites with
Surrounding Bases……………………………………………………………….34

v

1.

LIST OF FIGURES
Comparison of the Murine and Human Adiponectin Promoter Regions………...17

2.

PRL Treatment Decreases the Expression of Adiponectin in 3T3-L1
Adipocytes……………………………………………………………………….25

3.

PRL Stimulates Protein binding to the -3809 Site in the Mouse adiponectin
Promoter………………………………………………………………………….27

4.

Mutation of the consensus STAT5 Binding Sequence Ablates PRL Induced
Protein Binding to the -3809 Site………………………………………………...28

5.

Cold Competition Analysis Reveals that Unlabeled Probe can Compete for PRL
Activated Protein DNA Complexes……………………………………………...29

6.

PRL Induces STAT5A and STAT5B Binding to the -3809 Site in the Mouse
Adiponectin Promoter……………………………………………………………30

7.

Treatment with PRL Modulates Adiponectin Promoter/Reporter Construct
Activity in 3T3-L1 Adipocytes…………………………………………………..31

vi

ABSTRACT
Adiponectin is a hormone secreted from adipocytes that plays an important role in
insulin sensitivity and fatty acid oxidation. The secretion of adiponectin from adipose
tissue has been shown to be attenuated by treatment with prolactin (PRL). PRL is a potent
STAT5 activator, and studies have indicated that it can modulate the expression of
several genes in adipocytes. In this study, we demonstrate that 3T3-L1 adipocytes treated
with PRL exhibit a reduction in adiponectin levels. Furthermore, we identified three
putative STAT5 binding sites in the mouse adiponectin promoter and show that only one
of these, located at -3809, binds nuclear protein in a PRL dependent manner. Mutation of
the STAT5 binding site abrogated PRL dependent protein binding, and supershift
analysis revealed that STAT5A and 5B, but not STATs 1 and 3, bind to this site in
response to PRL. Promoter/reporter constructs containing the -3809 site were found to be
responsive to PRL. Taken together, these data strongly suggest that PRL regulates
adiponectin transcription through the binding of STAT5 to the -3809 site.
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CHAPTER 1. INTRODUCTION
1.1 Metabolic Syndrome and the Study of Adipocytes
The study of adipocytes is important because of the growing epidemic of obesity
in the United States and the world. Obesity is one of a number of interrelated symptoms
including, insulin resistance, hypertension, dyslipidemia, and glucose intolerance that are
collectively referred to as metabolic syndrome (1). Individuals with metabolic syndrome
have an increased risk of developing atherosclerotic cardiovascular disease as well as
type II diabetes, and the primary metabolic defects responsible for obesity have been
found to exacerbate all aspects of metabolic syndrome (1). Some studies have projected
that 50% of the population in the United States will become obese by the year 2025 (2),
therefore it is critical to understand the molecular mechanisms that contribute to the
pathogenesis of obesity and metabolic syndrome.
Obesity is a condition in which excess adipose tissue accumulates, so it is logical
to investigate the primary cell type in adipose tissue, the adipocyte. Mature adipocytes
possess three properties that largely distinguish them from other cell types. Firstly,
adipocytes are unique in their ability to store large amounts of lipid in the form of
triglyceride. Secondly, adipocytes are highly insulin sensitive, which is due largely to
their expression of the protein glucose transporter 4 (GLUT4). GLUT4 is an insulin
sensitive glucose transporter that is found exclusively in heart, skeletal muscle, and
adipocytes. Lastly, studies within the last fifteen years have revealed that adipocytes have
important endocrine functions. Indeed, several hormones are made exclusively in
adipocytes and referred to as adipokines. Adipokines have been shown to play critical
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roles in the metabolic homeostasis of the body, and obese individuals have been reported
to have an altered circulating adipokine profile that contributes to the etiology of
metabolic syndrome (3). The goal of this thesis is to elucidate whether the transcription
of adiponectin, an adipokine hypothesized to have protective effects against metabolic
syndrome, is regulated by the latent transcription factor Signal Transducer and Activator
of Transcription 5 (STAT5).
1.2 Adipocyte Cell Lines as a Model System
A lot of what is known about adipocyte biology today has been obtained from
studies on adipocyte cell lines. Several commonly used adipocyte cell lines were cloned
from the mouse embryonic fibroblast cell line 3T3 by Green and colleagues back in the
1970s. Green observed that out of 20 clones taken from the 3T3 stock, 19 of them
accumulated lipid to various degrees once confluence was reached (4). Only portions of
these confluent cell populations accumulated lipid and subpopulations prone to lipid
accumulation were selected and propagated giving rise to the 3T3-L1 and 3T3-F442A
cell lines used extensively in studies on adipocyte biology (5). The differentiation process
of these cell lines is thought to be similar to native adipocyte formation from
preadipocytes, and researchers have found ways to increase the rate of differentiation in
these cell lines by treating them with hormone cocktails containing: insulin, isobutylmethylxanthine (a phosphodiesterase inhibitor), dexamethasone (a synthetic
glucocorticoid), and fetal bovine serum. Upon differentiation, both cell lines possess the
major characteristics of native adipoctyes, and experiments have shown that injection of
3T3-F442A cells into athymic mice form fully developed fat pads, which substantiates
these cell lines as good model systems (6).
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1.3 JAK/STAT Signaling
Adipocytes possess a number of different signaling pathways, including the Janus
Kinase/Signal Transducer and Activator of Transcription (JAK/STAT) pathway. In this
pathway, cytokines bind to a non-enzymatic receptor associated with JAK that dimerizes
allowing JAK to transphosphorylate the opposite receptor. STAT proteins then bind to
the phosphorylated receptor, and they themselves are then phosphorylated by the receptor
associated JAK. Tyrosine phosphorylation of the STAT proteins allows them to dimerize,
dissociate, and translocate to the nucleus to modulate gene expression (reviewed in 10).
There are seven STAT proteins, but only five of these, STATs 1, 3, 5A, 5B, and 6
are expressed in mature adipocytes (7). The cytokine prolactin (PRL) strongly activates
STAT5 and to a lesser extent STATs 1 and 3 (8). PRL signaling follows the canonical
JAK/STAT pathway, but more specifically, when PRL binds the PRL receptor, the
receptor recruits JAK2 to phosphorylate the receptor and STAT5. It is largely unknown
what proteins are responsible for mediating the translocation of STAT5 through the
nuclear pore complex (NPC), but mutational analysis of asparagine 104 on STAT5 has
shown that this amino acid is essential for IL-3 dependent nuclear import of STAT5 and
suggests a required protein:protein interaction for STAT5 translocation (9).
1.4 STAT 5A and 5B
STAT5 represents two proteins, 5A and 5B, which are encoded for by separate
genes on chromosome 11 in mice and are expressed in all tissues at varying levels (10).
STAT5A and 5B are capable of forming both homo and heterodimers upon activation,
but the significance of this observation remains unclear in the context of gene regulation
(11). Both share 96% sequence similarity, and like all STAT proteins, possess a number
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of domains including: (in order from N-terminus to C-terminus) an N-terminal domain,
coiled-coil domain, DNA binding domain, Src Homology (SH) 3 domain, SH2 domain,
tyrosine activation domain, and transcriptional activation domain (TAD). Beginning at
the amino terminus, the amino terminal domain forms a ring structure consisting of 5
helices (12). This region has been reported to play an important role in STAT5 dimer and
tetramer formation, and mutation of tryptophan 37 within this region has been shown to
ablate tetramer formation (13). The coiled-coil domain consists of a flexible region of 4 α
helices that protrude from the core structure and serves as a docking site for proteins on
STAT proteins including N-Myc interactor (Nmi) on STAT 5B (14). The DNA binding
domain has been documented to bind DNA using a β barrel motif similar to those used by
the transcription factors p53 and NF-kB (14). Furthermore, X-ray crystallography studies
of STAT5A have revealed that the β barrel motif has a modest number of contact points
with bound DNA giving it a dissociation constant in the nanomolar range (15). Next, the
SH3 domain is thought to facilitate protein:protein interactions between STAT proteins,
although extensive interactions are known to occur among the other domains (16). An
SH2 domain lies next to the SH3 domain, and domain swapping studies have suggested
that the SH2 domain of each STAT family member is the sole determinant in which
STAT proteins are recruited to activated receptors (17). Additionally, the SH2 domain is
believed to facilitate the dimerization of STAT proteins by binding to the phosporylated
tyrosine residue on the oppositely bound STAT (18). Furthermore, like other STAT
members, STAT5 proteins contain a highly conserved tyrosine residue (Tyr694 on 5A,
Tyr699 on 5B) that is required for activation. An additional TAD domain is present at the
carboxyl terminus. STAT5A and 5B differ greatly in both the sequence and size of this
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domain, and studies have suggested that serine phosphorylation within this region may be
required for maximal activation of STAT5 proteins (19).
Knockout experiments of STAT5A and 5B have revealed both redundant and
non-redundant functions for these proteins. STAT5A knockouts exhibited defects in
mammary gland development and were infertile (20). The 5A knockout phenotype was
strikingly similar to prolactin receptor knockout mice, which suggests that prolactin
signals primarily through STAT5A (21). Likewise, male STAT5B knockout mice
exhibited a dwarf phenotype that was similar to growth hormone (GH) receptor knockout
mice, which suggests that GH signals primarily through STAT5B. STAT5B knockouts
were, however, sexually dimorphic because female mice did not exhibit stunted growth
(22). STAT5A/5B double knockouts exhibited severe dwarfism in both sexes, were
infertile, lacked proper mammary gland development, and had fat pads one-fifth the size
of wild type mice. These mice also had immune system defects including a lack of
natural killer cells, and numerous T cell and B cell abnormalities (23).
1.5 Prolactin and Growth Hormone
PRL is produced in the lactotroph cells of the anterior pituitary, as well as other
locations in the body (24;25). As its name implies, PRL plays a large role in the
production of milk in pregnant women, but other roles including modulating lipolysis
(26) and adipogenesis (27) have been identified. Interestingly, except in the case of
pregnancy, PRL levels in men and women are very similar and it has recently been
discovered that PRL is produced by adipose tissue in humans (28). As is the case with
other PRL production sites outside of the anterior pituitary, the PRL gene in adipose
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tissue is differentially regulated and under the control of a super distal promoter located 6kb away from the transcription start site (29;30).
GH is another known activator of STAT5, and is produced in the somatotroph
cells of the anterior pituitary gland. It is known that GH increases lipolysis and protein
synthesis, and decreases lipogenesis and glucose uptake (31). It is also known that
chronic exposure to GH results in reduced adipose tissue growth (32). Furthermore,
circulating GH levels are reduced during the condition of obesity (33). Overall, there are
numerous studies showing that GH is a prominent regulator of adipocyte metabolism
(34).
Both GH and PRL activate the phosphatidylinositol (PI) 3 kinase pathway as well
as the JAK/STAT pathway. Similarly, insulin utilizes the PI 3 kinase pathway, and
studies have shown that the effects of insulin on glucose transport, gluconeogenesis, and
lipogenesis are almost completely dependent on the actions of PI 3 kinase (35).
Numerous studies have indicated that chronically high levels of GH and PRL can cause
insulin resistance (36;37) , and it has been hypothesized that these actions involve the
modulation of PI 3 kinase activity. PI 3 kinase is activated via its recruitment to the
plasma membrane by Insulin Receptor Substrate (IRS) proteins which, in turn, are
activated by the insulin, PRL, and GH receptors, respectively. The structure of PI 3
kinase consists of a heterodimer containing a regulatory p85 subunit and a catalytic p110
subunit, each of which possess multiple isoforms (35). Knockout experiments of the p85α
isoform in mice exhibit a phenotype of increased insulin sensitivity (38). In addition,
other experiments have shown that the overexpression of p85α in cells results in
decreased glucose uptake and inhibited PI 3 kinase activity (39). Chronically high levels
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of GH have been shown to induce the transcription of the p85α subunit (40), which may
account for the concomitant loss of insulin sensitivity seen with this condition.
1.6 Regulation of the JAK/STAT Pathway
JAK/STAT signaling is regulated by a number of different protein interactions.
Dephosphorylation of activated signaling components by phosphatases such as SH2
protein tyrosine phosphatase 1 (SHP1) is one method cells use to regulate the JAK/STAT
pathway. SHP1 consists of two tandem SH2 domains as well as a phosphatase domain
which has been reported to bind to activated JAK2 (41). Another method of JAK/STAT
regulation comes from the activation of Suppressors Of Cytokine Signaling (SOCS)
proteins. The SOCS family consists of 8 members, SOCS 1-7 and Cytokine Inducible
SH2-containing (CIS) (42). SOCS 1-3 and CIS are activated by PRL (43). Upon
activation, SOCS proteins bind to an activated receptor or JAK and inhibit their
interaction with downstream signaling components. Additionally, SOCS proteins contain
a SOCS box motif that is known to recruit elongin B and C, two proteins involved in the
ubiquitination and subsequent proteasomal degradation of bound proteins. Contrary to
SOCS proteins, which are primarily activated by cytokines, Protein Inhibitors of
Activated STAT (PIAS) proteins are a constitutively expressed class of STAT inhibitors
found in a number of cell types. One PIAS protein, PIAS3, has been shown to inhibit
STAT5 signaling by binding and interfering with its ability to bind DNA (44).
Furthermore, PIAS proteins have been reported to function as Small Ubiquitin like
modifier (SUMO) E3 ligases (45). The functional consequence of SUMOylation can vary
depending on the targeted protein, but in the case of STATs, it is hypothesized to
modulate their activity (46).
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1.7 Genes Regulated by STAT5 in Adipocytes
STAT5 has been reported to play a role in the regulation of a number of genes in
adipocytes. A previous study has shown that STAT5 plays a role in lipid accumulation in
mature adipocytes and showed that STAT5 activation represses the induction of fatty acid
synthase (FAS) (47). Furthermore, another study has shown that STAT5 binds to the
Acyl CoA oxidase (AOX) promoter and that treatment with STAT5 activators causes an
increase in AOX mRNA (48). STAT5 has also been reported to play a role in insulin
resistance and can induce the expression of pyruvate dehydrogenase kinase 4 (PDK4) in
adipocytes (49). PDK4 is a kinase that is known to phosphorylate and inactivate the
pyruvate dehydrogenase complex (PDC), the protein responsible for converting pyruvate
into acetyl CoA in mitochondria. Hence, when PDC becomes inactive, glucose levels rise
within the cell which leads to hyperglycemia. This observation correlates well with a
study that showed that PDK4 activity and expression increases in type II diabetics (50).
STAT5 has also been reported to play an important role in the activation of genes
encoding milk proteins. In fact, STAT5 was initially named mammary gland factor
(MGF), because it was first discovered as an activator of the milk protein β casein (51).
1.8 Protein Interactions with STAT5
A number of studies have shown that proteins that interact with STAT5 can have
a modulatory effect on its function. The transcription factor CCAAT Enhancer Binding
Protein (C/EBPβ) has been found to associate with STAT5 in the presence of the
glucocorticoid receptor (GR), which together form a complex that induces the
transcription of the β casein gene (52). Additionally, STAT5 has been found to relieve
repression of the β casein gene by interacting with Yin-Yang factor 1 (YY1), a protein
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that binds next to the STAT5 response element on the β casein promoter and inhibits β
casein transcription in the absence of STAT5 (53). Similarly, STAT5 has been reported
to form an enhancer complex with an adjacent binding transcription factor, Sp1, in the
promoter region of cyclin D2 (54). Moreover, studies have shown that STAT5 interacts
with the histone acetylase Creb Binding Protein (CBP)/P300 which serves as a
coactivator of the β casein gene (55). This interaction is enhanced by the protein Nmi,
which binds not only STAT5 but other members of the STAT family as well (56).
1.9 Adiponectin
Adiponectin is an adipokine that has recently come into the spotlight as a major
player in the control of energy homeostasis. The adiponectin gene encodes a protein that
circulates in serum as high and low molecular weight oligomers (57). A proteolytic
cleavage product known as globular adiponectin has also been reported (58). Low
circulating levels of adiponectin have been associated with an increased risk of
cardiovascular disease (CVD) (59). Men have a higher incidence of CVD than women
(60), and studies have shown that adiponectin levels on average are lower in men than in
women (61) which suggests a possible link between low adiponectin levels and the
development of CVD. Low adiponectin levels have also been observed in obese patients
(62), and mice lacking adiponectin experience severe hepatic insulin resistance (63).
Hence, administration of adiponectin to obese animal models with type II diabetes has
shown that adiponectin can help alleviate insulin resistance in these models (64).
Moreover, a higher ratio of high molecular weight oligomer/total adiponectin levels has
been correlated with higher insulin sensitivity, and appears to be more important than
total adiponectin levels in regards to insulin sensitivity (65). Adiponectin is also known to
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activate AMP activated kinase whose activity involves increasing fatty acid oxidation and
increasing glucose transport (66). A recent study also revealed that adiponectin appears to
play a role in signaling the allocation of triglyceride to white adipose tissue, away from
other storage sites such as the liver and muscle which are considered to be metabolically
unhealthy “spill over” sites for fat storage when white adipose tissue becomes unable to
store excess triglyceride (67).
1.10 Adiponectin Receptors
Two receptors for adiponectin have been identified thus far, AdipoR1 and
AdipoR2. AdipoR1 is expressed ubiquitously and is most abundant in skeletal muscle,
whereas AdipoR2 is primarily expressed in the liver (68). Human and mouse adipoR1
and adipoR2 share 96.8% and 95.2% sequence similarity, respectively (69). The gene for
AdipoR1 resides on chromosome 1p36.13-q41 in humans and 1E4 in mice and AdipoR2
is located on chromosome 12p13.31 in humans and 6F1 in mice (70). AdipoR1 and
AdipoR2 share 66.7% sequence identity and both are predicted to form 7 transmembrane
domain proteins similar to receptors belonging to the G-protein-coupled receptor (GPCR)
families. However, GPCR receptors and adiponectin receptors are only distantly related
because the N-terminus of the adiponectin receptor resides in the cytosol and the Cterminus resides externally which is opposite to that of typical GPCR receptors. It has
also been shown that globular adiponectin binds to AdipoR1 with a higher affinity than
AdipoR2 and that full length adiponectin binds to AdipoR2 more tightly than AdipoR1
(71). Human studies have revealed that AdipoR1/R2 mRNA is upregulated after exercise
in human skeletal muscle (72). Furthermore, families with a history of type II diabetes
have been reported to have lower AdipoR1/R2 expression levels than families without a
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history of type II diabetes (73).
1.11 Actions of Adiponectin
A number of studies have shown that adiponectin increases insulin sensitivity and
fatty acid oxidation throughout the body. When adiponectin binds to one of its receptors,
the protein Adaptor-Protein containing Pleckstrin and phosphotyrosine domains and
Leucine zipper motif (APPL1) associates with the receptor and becomes activated (74).
Upon activation, APPL1 has been documented to associate with the monomeric GTPase
Rab5, which is known to play a major role in endocytosis (75). APPL1 has also been
reported to activate the protein kinase LKB1, a known tumor suppressor that lies
upstream of AMP kinase (AMPK). AMPK is a heterotrimeric protein that consists of a
catalytic α subunit and two regulatory β and γ subunits. AMPK serves as the global
energy regulator of the cell by detecting the ratio of 5’-AMP/ATP, where 5’-AMP
activates AMPK and 5’-ATP inhibits AMPK. One mechanism in which AMPK increases
fatty acid oxidation is by phosphorylating acyl-CoA carboxylase (ACC) (76).
Phosphorylated ACC results in a reduction of malonyl-CoA production, an inhibitor of
long chain acyl-CoA carnitine palmitoyltransferase 1 (CPT1). Thus, low levels of
malonyl-CoA result in increased transport of long chain acyl-CoA into the mitochondrial
matrix resulting in increased fatty acid oxidation.
Adiponectin signaling has been reported to activate p38 Mitogen Activated
Protein Kinase (MAPK) (77). The MAPK kinases (MAPKK) MEK3 and MEK6 are
responsible for activating p38 MAPK, however, it is unknown how MEK3 and MEK6
are activated by adiponectin because they lie downstream from numerous upstream
MAPKK kinases (MAPKKK) (78). Activated p38 MAPK phosphorylates and activates
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PPARα, a nuclear receptor that, like PPARγ, forms an obligate heterodimer with the
retinoid X receptor (RXR). PPARα is responsible for the transcriptional control of
numerous enzymes responsible for fatty acid oxidation and is activated not only by p38
MAPK, but ligands such as arachidonic acid derivatives, long chain fatty acids, and
fibrates (79). Activated PPARα upregulates the expression of Fatty Acid Transport
Binding Protein (FATP), as well as a host of enzymes involved in β oxidation such as
medium chain acyl CoA dehydrogenase (MCAD), acyl CoA Oxidase (ACO), and
cytochrome P450 fatty acid ω-hydroxylase (80).
Adiponectin is also responsible for increased insulin sensitivity in numerous cell
types. A mechanism for this action has been hypothesized by Wang et al. in C2C12
myotubes that involves prolonging the activation of Insulin Receptor Substrate 1 (IRS-1)
in response to insulin by inhibiting S6 kinase, an inhibitor of IRS-1 (81). S6 kinase is
activated by the mammalian Target Of Rapamycin (mTOR)/raptor complex, and
treatment with rapamycin, an mTOR/raptor inhibitor, decreased the activity of S6 kinase
on IRS-1. Interestingly, treatment with adiponectin also inhibited S6 kinase activity on
IRS-1 and further experimentation revealed a likely pathway in which AMPK (activated
by adiponectin) activates the tuberous sclerosis complex (TSC1/2), which inhibits Ras
homology enriched in brain (Rheb), an activator of the mTOR complex. Thus, a possible
pathway for the insulin sensitizing effects of adiponectin has been shown in C2C12
myotubes.
1.12 Single Nucleotide Polymorphisms of the Adiponectin Gene
The human adiponectin gene is located on chromosome 3q27, which is a region of
DNA in which more than a dozen Single Nucleotide Polymorphisms (SNPs) have been
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linked to type II diabetes and metabolic syndrome (82-84). SNPs within the proximal
promoter of adiponectin have been identified and it has been observed that individuals
with an SNP of G/G at -276 of the transcription start site (the binding site of PPARγ)
have a two fold higher risk of developing type II diabetes when compared to individuals
with an SNP of T/T (85). Other more distally located SNPs have been found at -11377
and -11391 and are associated with hypoadiponectinemia and type II diabetes (86). SNPs
with metabolic implications within the adiponectin gene itself have also been identified.
Individuals with SNP 45 on exon 2 independently or combined with the -276 SNP exhibit
an increased risk of obesity and insulin resistance (87). Moreover, individuals with an
I164T missense mutation have been observed to have significantly lower levels of
adiponectin independent of body mass index (BMI) (88).
1.13 Transcriptional Control of Adiponectin
Numerous studies have examined the transcriptional control of the human
adiponectin gene. Deletion analysis of the human adiponectin promoter region has
demonstrated that the region from -676 to +41 is sufficient for basal level transcription
activity (89). Furthermore, mutation analysis of response elements for Sterol Regulatory
Element Binding Protein (SREBP) -423 and CCAAT/enhancer binding protein (C/EBP)
at -224 has shown that both sites are necessary for basal level transcription (90). Another
study has revealed that there are multiple C/EBPα sites within the first intron of the
human adiponectin gene that serve to enhance basal level transcription (91). The
adiponectin promoter also contains a Peroxisome Proliferator Activated Receptor γ
(PPARγ) response element (PPRE) at -273 that allows the nuclear receptor PPARγ to
activate the adiponectin gene (92). Activation of the adiponectin gene can also be
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achieved through the use of thiazolidinediones, a class of drugs that serve as artificial
PPARγ agonists. Moreover, an orphan nuclear receptor known as Liver Receptor
Homolog-1 (LRH-1) has been reported to bind to -229 of the human adiponectin
promoter and mutation analysis of this binding site has revealed that it is required for
both basal and induced transcription (93).
The promoter region of adiponectin in mice has also been extensively studied.
The transcription factor forkhead transcription factor O1 (FOXO1) has been reported to
bind the mouse promoter at -670 and -610 and serves to upregulate adiponectin. FOXO1
is a known target of protein kinase B (PKB), a protein kinase activated by insulin and
various growth factors (94). Phosphorylation of FOXO1 by PKB results in its exclusion
from the nucleus and renders it incapable of inducing the transcription of adiponectin.
Moreover, FOXO1 has been found to form a complex with C/EBPα at these sites (95),
and this interaction is enhanced by the protein deacetylase Silent Information Regulator 2
Mammalian Ortholog (SIRT1), which deacetylates 3 lysine residues in the forkhead DNA
binding domain (96). Furthermore, a study in mice has shown that C/EBP and Nuclear
Factor-Y (NF-Y) bind the -73 to -117 region of the adiponectin promoter and that
mutation or deletion of this region results in dramatically reduced transcription levels
(97).
Sequence analysis of the human and murine adiponectin promoters reveal a
number of potential transcription factor binding sites that are unpublished. Similar to the
human LRH-1 site previously described (74), a potential LRH-1 site is located at -124 of
the murine adiponectin promoter that resembles an LRH-1 binding site found at -48 and 55 of the rat Cyp8b1 gene (98) (Table1). Furthermore, the murine adiponectin promoter
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contains a potential PPARγ response element (PPRE) at -554 similar to those found in
other genes including the ARE7 site found in the mouse AP2 gene (99) (Table 1).
Moreover, a possible NF-Y binding site is present at -380 of the human adiponectin
promoter (Table 1), which is similar to the sites already found in the murine adiponectin
promoter (78). A comparison of the mouse and human adiponectin promoter regions is
presented in figure 1.
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Table 1. Comparison of Promoter Response Elements

Gene

LRH-1 Sequence

Position

Human adiponectin

TCAAGGCCT

-229 (ref. 74)

Rat Cyp8b1

GCAAGGTCC

-55 (ref. 79)

Rat Cyp8b1

CCAAGGGCA

-48 (ref. 79)

Mouse adiponectin

GCAAGGGCA

-124 (putative)

Gene

PPRE Sequence

Human adiponectin

GGGCA A AAGTCA

-273 (ref. 74)

Mouse AP2

TGAACT C TGACCC

ARE7 (ref. 80)

Mouse adiponectin

TGAACT C AGGACC

Gene

NF-Y Sequence

Position

-554 (putative)

Position

Mouse Adiponectin

ATTGG

-73 (ref. 78)

Human Adiponectin

ATTGG

-380 (putative)

16
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STAT* (-3394)

Human

Transcription Start Site

STAT* (-3196) Foxo1 (-670,-610) PPAR/RXR* (-554) LRH-1* (-124) C/EBP and NF-Y,A,C (-73)

Transcription Start Site

Fig. 1. Comparison of the Murine and Human Adiponcetin Promoter Regions. The figure above represents published
and potential transcription factor binding sites for the murine and human adiponectin promoter regions. The * symbol denotes
unpublished sites found using the www.ensemble.org genome database: murine accession # ENSMUST00000023593, human
accession # ENST00000320741.
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CHAPTER 2. MATERIALS AND METHODS

2.1 Materials
STAT5A and adiponectin antibodies were purchased from Santa Cruz
Biotechnology. [α-32P] dCTP was purchased from Perkin-Elmer and dTTP, dATP, dGTP
were purchased from Amersham Biosciences. Klenow and Klenow buffer were
purchased from Promega. Fetal bovine serum (FBS) was purchased from Atlanta
Biologicals and calf serum was purchased from Biosource. Sheep prolactin was
purchased from Sigma. Bicinchoninic Acid (BCA) was purchased from Pierce.
Oligonucleotide probes were ordered from Integrated DNA Technologies.
2.2 Cell Culture
Murine 3T3-L1 preadipocytes were plated and grown to 2 days post-confluence in
Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% bovine serum.
Medium was changed every 48 hours. Preadypocytes were differentiated into adipocytes
by changing the medium to DMEM containing 10% fetal bovine serum, .5 mM 3isobutyl-methylxanthine, 1 uM dexamethasone, and 1.7 uM insulin (MDI). After 48
hours, medium was replaced with DMEM supplemented with 10% FBS and cells were
allowed to differentiate for 5 days. After differentiation, medium was changed every 48
hours and fully differentiated adipocytes were maintained until harvested for
experimentation.
2.3 Preparation of Nuclear and Cytosolic Extracts
Cell monolayers were rinsed with PBS buffer and nuclear homogenization buffer
(NHB) was added containing 20 mM Tris (pH 7.4), 10 mM NaCl, 3 mM MgCl2, 1 uM of
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dithiothreitol, 1 uM phenylmethylsulfonyl fluoride, 1 uM pepstatin, 50 trypsin inhibitory
milliunits of aprotinin, 10 uM leupeptin, and 2 mM sodium vanadate. Igepal CA-630
(Nonidet P-40) was added to a concentration .15% before each extraction and
homogenized 16 times in a Dounce homogenizer. Resulting homogenates were then
centrifuged at 1500 rpm for 5 minutes at 4°C. Supernatants were decanted and saved as
cytosolic extracts. The nuclear pellets were then resuspended in ½ the volume of NHB
used previously and centrifuged as before twice to wash the nuclei. The nuclei pellet was
then resuspended in extraction buffer containing 20 mM HEPES (pH 7.9), 420 mM NaCl,
1.5mM MgCl2, .2mM EDTA, 1 uM dithiothreitol, 1 uM phenylmethylsulfonyl fluoride, 1
uM pepstatin, 50 trypsin inhibitory milliunits of aprotinin, 10 uM leupeptin, 2 mM
sodium vanadate, and 25% glycerol. Nuclei were then extracted on ice for 30 minutes to
1 hour with frequent inversion to ensure proper extraction. Afterwards, samples were
centrifuged at 10,000 rpm at 4°C for 10 minutes to pelletize cell debris. Supernatants
containing the nuclear extracts were then analyzed for protein content using the BCA
assay kit, aliquoted, and frozen at -80°C for later use.
2.4 Preparation of Whole-Cell Extracts
Cell monolayers were rinsed with PBS and then harvested in a non-denaturing
buffer containing 10mM Tris (pH 7.4), 150 mM NaCl, 1mM EGTA, 1mM EDTA, 1%
Triton X-100, 0.5% Nonidet P-40, and 1 uM phenylmethylsulfonyl fluoride. A protease
inhibitor cocktail was added to this buffer before each experiment consisting of 1 uM
phenylmethylsulfonyl fluoride, 1 uM pepstatin, 50 trypsin inhibitory milliunits of
aprotinin, 10 uM leupeptin, and 2mM sodium vanadate (a phosphatase inhibitor).
Samples were extracted for 30 minutes on ice and centrifuged at 15,000 rpm at 4°C for

19

15 minutes. Supernatants containing whole cell extracts were analyzed for protein content
by bicinchoninic acid (BCA) analysis according to the manufacturer’s protocol.
2.5 Western Blotting
Whole cell extracts were run on a 7.5% polyacrylamide gel containing SDS using
the Laemmli method (100). Proteins were transferred to nitrocellulose (Bio-Rad) in 25
mM Tris, 192 mM glycine, and 20% methanol under a current of 55 volts for 4 hours at
4°C. After transfer, nitrocellulose membranes were blocked overnight in TBS buffer
(.025M Tris, .125M NaCl, .1% Tween 20) containing 4% powdered milk. Nitrocellulose
membranes were washed twice for 10 minutes on an orbital shaker and exposed to rabbit
derived primary antibodies specific for adiponectin or STAT5A for 1.5 hours.
Membranes were then washed for 15 minutes in TBS buffer 3 times and exposed to
rabbit specific secondary antibodies conjugated to horseradish peroxidase (Jackson
ImmunoResearch Laboratories) for 1.5 hours. Afterwards, membranes were washed for
10 minutes in TBS buffer 3 times and visualized using enhanced chemiluminescence
(Pierce) according to the manufacturer’s protocol.
2.6 Electrophoretic Mobility Shift Assay (EMSA)
Primary and complementary DNA oligonucleotide strands (Table 2) were
combined (10 ug each strand) and heated for 5 minutes in a 95°C water bath.
Oligonucleotide strands were allowed to cool and anneal overnight forming double
stranded oligonucleotide probes. Oligonucleotide probes were radioactively labeled by
combining 4 ug of DNA probe with Klenow, Klenow buffer, 20 uCi α-32P dCTP, .33 mM
dATP, dGTP, dTTP, and incubating the reaction for 15 min. at 30°C. The reaction was
stopped by adding 1 ul of .5M EDTA. Probes were purified from the reaction mixture
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using micro Bio-Spin 30 chromatography columns (Bio-Rad). Probe purity was measured
by running samples on TLC plates (Sigma) in a reservoir of .5 M KH2PO4 and exposing
the plates to autoradiography film. Specific probe activity was measured by scintillation
and typically measured 50,000 cpm/ul. Samples were prepared using the method
described by Ritzenthaler (101) and loaded onto a pre-run (200V for 1 hour at 4°C) TBE
gel consisting of 6% polyacrylamide/bisacrylamide (40:1 polyacrylamide to
bisacrylamide), 90 mM Tris, 90 mM boric acid, and 2 mM EDTA, pH 8.0. Cold
competition experiments were performed by serial diluting 2 µl of stock unlabled probe
two fold for each successive sample and combining 1 µl of diluted probe with 1 µl
radiolabeled probe before incubation with nuclear extracts. Supershift analysis was
performed by incubating 1.5 ug/ul of antibody with nuclear extracts for 1 hour at room
temperature prior to incubation with the DNA probe.
2.7 Plasmid Construction
The region corresponding to the -3809 site and the 125 bp flanking it were
amplified by PCR. PCR primers were designed using the primer 3 progam which can be
found at the website http://biotools.umassmed.edu/bioapps/primer3_www.cgi. Restriction
sites for NheI and HindIII were added to primer ends to facilitate directional cloning
(Table 3). PCR reaction conditions consisted of 45 µl of platinum PCR supermix HiFi
(Invitrogen), .5 µl of each primer from a 20 picomolar stock, and 100 ng of genomic
DNA from 3T3-L1 adipocytes. PCR was performed using an MJ Research PTC-100
machine set to cycle at 1) 94° for 2 minutes 2) 94° for 30 seconds 3) 55° for 30 seconds
4) 68° for four and a half minutes, which was then repeated 35 times beginning with step
2. Amplicons were purified and digested with NheI and HindIII according to the
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Table 2. Primary and Complementary DNA strands Used in EMSAs

Site

Primary Strand

-3196

5’-GGAGTGTTCTCAGAAAATGAAAAAA-3’

-3394

5’-ACTGGCCTTCGGAGAAAAG-3’

-3809

5’-GAGGCCCTGAATTCTAATTCCCAGAA-3’

β-Casein

5’-GCCATGGTTTTCTTGGAACTCACTAT-3’

Site

Complementary Strand

-3196

5’-TTTTTTCATTTTCTGAGAA-3’

-3394

5’-TGACTTGCTTTTCTCCGAA-3’

-3809

5’-GTGGTTTCTGGGAATTAGAATTCAGG-3’

β-Casein

5’-GAGGCCCTGAATTCTAATTCCCTTAA-3’

manufacturer’s instructions (New England Biolabs). The pGL4.27 luciferase vector
(Promega) was also digested with NheI and HindIII and ligated to the previously digested
amplicons by using T4 DNA ligase according to the manufacturer’s instructions (New
England Biolabs) giving rise to the PGL4-Adipo construct.
2.8 Transformation and Plasmid Preparation
One Hundred microliters of Dh5α competent cells (Invitrogen) were diluted five
fold in Tris-HCl (pH 7.5) and 1 mM EDTA. One microliter of DNA (containing 1-10ng
DNA) was added and cells were incubated on ice for 30 minutes. Cells were then
transformed by heat shock for 45 seconds in a 42°C water bath and placed on ice for 2
minutes prior to the addition of .9 ml of room temperature S.O.C. medium. Cells were
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then shaken at 225 rpm, 37°C for 1 hour and diluted 1:10 with S.O.C. medium. One
hundred microliters from this suspension was then spread on fresh LB plates containing
100 µg/ml of ampicillin before being placed in a 37°C incubator overnight. Colonies
from overnight plates were used to inoculate 20 ml of LB broth containing 100 µg/ml of
ampicillin and grown for 8 hours. Cells were diluted 1:1000 and grown for 12-16 hours in
LB broth containing 100 µg/ml of ampicillin. Afterwards, cells were pelleted by
centrifugation at 6,000 x g for 15 minutes at 4°C. Plasmids were isolated from cell pellets
using a Qiagen endofree maxi kit according to the manufacturer’s instructions.
Table 3. PCR Primers Used in This Study

Name

Sequence

Restriction Site

PGL4-Adipo

5’-GATCGCTAGCATGCAGGGCTCTCTGTTTTG-3’

Nhe1

PGL4-Adipo

5’-GATCAAGCTTGGAGCAACTGGAGCCAACTA-3’

Hind3

2.9 Transfections and Luciferase Assays
3T3-L1 adipocytes were differentiated for 6-8 days. Next, differentiation medium
was removed and cells were washed twice with PBS buffer and trypsinized using 5x
trypsin (Sigma) for 1 minute. Trypsinization was stopped by re-adding differentiation
medium supplemented with 4% glycerol and cells were centrifuged at room temperature
for 5 minutes at 90 g. Next, cells were resuspended in 10 ml of differentiation medium
supplemented with 4% glycerol and cell density was determined using a hemocytometer.
An appropriate number of cells (2 x 106 cells per 100 µl) were then centrifuged at room
termperature for 5 minutes at 90 g. Cells were resuspended to a volume containing 2x106
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cells per 100 μl in room temperature nucleofector L solution (Amaxa) and 2.5 μg of
PGL4-Adipo was added, along with 250 ng of CMV/renilla vector to control for
transfection efficiency. Amaxa cuvettes were loaded with 100 μl of cell suspension and
transfection was performed using program A-033 on an Amaxa Nucleofector II device.
After transfection, 500 µl of pre-warmed differentiation medium was added to the cells in
the cuvette and cells were transferred to one well in a 6 well plate containing 2 ml of prewarmed differentiation medium. Re-plated cells were allowed to grow for 2 hours until
medium was changed to DMEM containing 1% calf serum. Upon changing the medium,
cells were treated with 450 nM PRL or left untreated and grown for 48 hours. Cells
previously treated with PRL were treated again after 24 hours and after 48 hours cells
were aspirated and washed twice with PBS buffer before being lysed with 500 µl of
passive lysis buffer (Promega). PGL-4 Adipo activity was quantified by adding 20 μl of
cell lysate to 100 µl of LARII reagent (Promega) and mixed by pipetting 2-3 times before
being placed in a Berthold Detection Systems Sirius luminometer set to automatically
read after closing the sample door with a 2 second pre-measurement delay followed by a
10 second measurement interval. Immediately following luciferase detection, cotransfected CMV/renilla vector was measured by adding100 μl of Stop and Glo reagent
(Promega) and samples were briefly vortexed before being placed back in the
luminometer for detection. Relative light units (RLU) were calculated by dividing firefly
luciferase activity by renilla luciferase activity.
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CHAPTER 3. RESULTS
3.1 Prolactin Treatment Results in a Time Dependent Decrease in Adiponectin
Expression in 3T3-L1 Adipocytes
Previous studies have shown that PRL can cause a decrease in adiponectin
expression in human adipose tissue explants as well as mice (102). PRL is a potent
STAT5 activator, therefore we hypothesized that STAT5 may play a role in the hormonal
induced down regulation of adiponectin expression. To determine if fully differentiated
3T3-L1 adipocytes were chronically treated every 24 hours with 1 nM PRL for 96 hours.
Cells were harvested at various time points and western blot analysis was performed on
whole cell extracts (Fig. 2). These studies revealed that adiponectin levels were

0

12

24

48

72

96

Hours Prolactin

30 kD

Adiponectin

95 kD

STAT 5A

Lane

1

2

3

4

5

6

Fig. 2. PRL treatment decreases the expression of adiponectin in 3T3-L1 adipocytes.
Fully differentiated 3T3-L1 adipocytes were maintained in DMEM containing 10% FBS
and treated with 1 nM PRL every 24 hours until harvested at the times indicated. Forty
micrograms of whole cell extract were subjected to SDS-PAGE and transferred to
nitrocellulose for western blot analysis. STAT5A levels are shown as a loading control.
This is a representative experiment independently performed 2 times.
decreased within 48 hours and remain lowered for the duration of PRL treatment.
STAT5A levels are shown to indicate even loading of protein samples.
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3.2 Prolactin Treatment Induces STAT5 Binding of the Murine Adiponectin
Promoter in vitro
To determine if the down regulation of adiponectin was due to transcriptional
repression by PRL activated STAT5, we analyzed the first 4,000 bp of the adiponectin
promoter for consensus STAT5 binding sites (TTC NNN GAA). Three consensus STAT5
binding sites were identified at -3196, -3394, and -3809 bp from the transcription start
site (Table 4). To evaluate if these sites bound protein in response to PRL, EMSA
analysis was performed using nuclear extracts obtained from serum deprived cells treated
with 20 nM PRL for 15 minutes. As seen in figure 3, the site at -3809 binds to PRL
induced nuclear protein complexes, where as the sites at -3196 and -3394 sites do not
bind protein in response to PRL. The well characterized prolactin responsive STAT5
Table 4. PRL Responsive Sequences

Position

Sequences

PRL-Responsive

-3196

TTC TCA GAA

No

-3394

TTC GGA GAA

No

-3809

TTC TGG GAA

Yes

-3809 Mutant

TTA AGG GAA

No

β-Casein

TTC TAG GAA

Yes

binding site at -119 of the β casein promoter was analyzed as a positive control (Fig. 3,
lane 8). Nuclear extracts obtained from untreated cells were used as a negative control
and did not result in protein binding to the -3809 site. To show binding specificity for the
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Murine Adiponectin β‐casein
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Fig. 3. PRL stimulates protein binding to the -3809 site in the mouse adiponectin
promoter. Nuclear extracts were prepared from serum deprived 3T3-L1 adipocytes
untreated or treated with 20 nM PRL for 15 minutes. Radiolabled probes corresponding
to potential STAT5 binding sites with an activity of 50,000 cpm/ml were incubated with
10 µg nuclear extracts and subjected to EMSA analysis to analyze for binding activity. A
probe corresponding to a known STAT5 binding site in β casein promoter is included as a
positive control. This is a representative experiment independently performed two times.
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-3809 site, EMSA analysis was performed using probes with a mutated STAT5 binding
site (Table 4). Mutation of the consensus STAT5 binding site resulted in the ablation of
PRL responsive protein binding to the -3809 site (Fig. 4). Additionally, cold competition
experiments were performed and showed that increasing concentrations of unlabeled
-3809 probe were able to compete for PRL dependent protein binding (Fig. 5), and that
unlabeled β casein probe was also able to compete for protein binding (Fig. 5, lane 9).

M

WT
PRL

Lane

-

1

+

2

+

3

Fig. 4. Mutation of the consensus STAT5 binding sequence ablates PRL induced
protein binding to the -3809 site. Wildtype and mutant probes (Table 3) were incubated
with 10 µg PRL treated nuclear extracts and subjected to EMSA analysis. This is a
representative experiment individually performed two times.
To determine if PRL activated STAT proteins bound to the -3809 site, we
performed supershift analysis using antibodies specific for STAT proteins known to be
activated by PRL. As shown in figure 6, an antibody for STAT5A partially shifted the
PRL induced complex more than the antibody for STAT5B. This may be due to PRL
preferentially activating STAT5A more than STAT5B (11). Nonetheless, these shifts
indicate that both STAT5A and STAT5B bind the -3809 site in response to PRL in vitro.
Furthermore, antibodies specific for STATs 1 and 3 were unable to shift the PRL
activated complex, which indicates that these proteins do not bind to the -3809 site in
response to PRL treatment.
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Fig. 5. Cold competition analysis reveals that unlabeled probe can compete for PRL
activated protein-DNA complexes. 32P radiolabeled probe with an activity of 50,000
cpm/ml was serial diluted with 50 nM to 5 µM of unlabeled probe and combined with 10
µg of PRL treated nuclear extracts. Five micromoles of unlabeled β casein probe was
used in lane 9. Complexes were resolved by EMSA. This is a representative experiment
independently performed two times.
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Fig. 6. PRL induces STAT5A and STAT5B binding to the -3809 site in the mouse
adiponectin promoter. Ten micrograms of PRL treated nuclear extract was incubated
with 1.5 ug antibody specific for indicated STAT proteins for 1 hour at room temperature
prior to incubation with 50,000 cpm/ml of radiolabeled -3809 probe. Complexes were
resolved by EMSA. This is a representative experiment independently performed three
times.
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3.3 Luciferase Assay
In order to determine if the adiponectin promoter was responsive to PRL
treatment in living cells, fully differentiated 3T3-L1 adipocytes were transiently
transfected with the PGL4-Adipo vector containing the -3809 site and the 125 bp
surrounding it. Cells were left untreated or treated with 450 nM of PRL for 48 hours and
luciferase activity was measured using a Berthold Detection Systems Sirius luminometer.
PRL treated cells exhibited an increase in luciferase activity compared to cells left
untreated (Fig 7). Thus, stimulation with 450 nM of PRL appears to cause an increase in
PGL4-Adipo activity.
Expression of the PGL4-Adipo Promoter/Reporter Construct
in 3T3-L1 Adipocytes 48 Hours After Transfection
0.04
0.035
0.03
RLU

0.025
- PRL

0.02

+ PRL

0.015
0.01
0.005
0
Cell Treatment

Fig. 7. Treatment with PRL modulates adiponectin promoter/reporter construct
activity in 3T3-L1 adipocytes. Fully differentiated adipocytes were transiently
transfected with the PGL-4 Adipo vector containing the -3809 site and the 125 bp
flanking it. PRL treated cells were stimulated with 450 nM of PRL for 48 hours and a
CMV/renilla vector was co-transfected to account for transfection efficiency. Relative
light units (RLU) were calculated by dividing firefly luciferase activity by renilla
luciferase activity. Results were done in triplicate. This is a representative experiment
independently performed 3 times.

31

CHAPTER 4. DISCUSSION
4.1 Summary
Adiponectin levels in 3T3-L1 adipocyte whole cell extracts were shown to
decrease over time in response to chronic PRL treatment. PRL is a potent STAT5
activator, therefore the mouse adiponectin promoter was scanned for potential STAT5
binding sites. After scanning, three classical STAT5 binding sites were found and EMSA
analysis revealed that one site, at -3809, bound protein complexes in response to PRL.
Four independent pieces of data showed that STAT5 specifically bound to the -3809 site.
First, cold competition experiments showed that the prolactin induced protein complex
could be specifically competed for by unlabeled oligonucleotide probe corresponding to
the -3809 site. Secondly, unlabeled oligonucleotide probe corresponding to the well
characterized STAT5 binding site in the β casein promoter was also able to compete for
PRL induced complex binding. Moreover, EMSA supershift analysis showed that both
STATs 5A and 5B specifically bound to this site, where as STATs 1 and 3 did not.
Lastly, mutation of the STAT5 binding site resulted in the ablation of PRL induced
protein complex binding which suggests that a classical STAT5 binding site is necessary
for protein complex formation.
Luciferase experiments indicated an elevation in PGL4-Adipo activity upon
stimulation with PRL. These results may be an artifact of the PGL4-Adipo vector, (which
uses the -3809 site and the 125 bp surrounding it to drive the expression of the luciferase
gene) because the full length adiponectin promoter may contain response elements that
work in cooperation with the STAT5 binding site to silence adiponectin gene
transcription. Furthermore, dose dependency experiments (data not shown) demonstrated
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that 450 nM of PRL caused the most potent activation of STAT5, however, lower doses
of PRL could potentially have a different effect on PGL4-Adipo activity.
4.2 Possible Mechanisms of Adiponectin Regulation
The reduction in adiponectin protein levels is likely due to STAT5 binding to the
adiponectin promoter, which eventually causes the down regulation of the adiponectin
gene. Yet, adiponectin protein levels do not decrease until roughly 48 hours after PRL
treatment. The cause of this delay may be due to the stability of adiponectin mRNA,
however, since western blot analysis was done using cells maintained in DMEM
containing 10% FBS, the upregulation of the adiponectin gene by transcription factors
activated by growth factors in the media cannot be ruled out. Therefore, luciferase assays
were performed using 1% calf to help minimize the effects that other growth factors may
have on adiponectin gene expression.
Similar studies have been performed on a STAT5 binding site approximately
4000 bp away from the transcription start site of the Interleukin 2 Receptor α (IL2Rα)
(103). This site not only contains a consensus STAT5 binding site, but a partial STAT5
binding site 11 bp away which has been shown to facilitate the tetramerization of STAT5
proteins (104). In addition, mutation of N-terminal STAT5 residues ablated tetramer
formation and resulted in the loss of STAT5 activity on the IL2Rα gene. Interestingly, we
have observed that the site found at -3809 also contains a partial STAT5 binding site
located 6 bp away (Table 5). Extensive studies have been made showing enhanced
STAT5 binding activity to tandem STAT5 binding sites (105), and it has been suggested
that oligomerization of STAT proteins may contribute to DNA binding specificity (106),
therefore binding to the -3809 site may be due to the presence of a partial STAT5 binding
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site. Other studies have shown that activation of STAT5 alone cannot modulate the
expression of the IL2Rα gene (107), and that cooperation with other transcription factors,
such as Elf-1, are necessary for full activity. Thus, the activity of STAT5 on the
adiponectin gene likely involves the recruitment of a number of proteins that work in
cooperation to turn off adiponectin gene transcription.
Table 5. Human and Murine Adiponectin Promoter STAT5 Binding Sites with
Surrounding Bases
Sequence

Location from Transcription Start Site

5’-ggaacttccccacaccccagttctcagaattcatgtgcaaggtctttcc-3’

- 561 (Human)

5’-tgccacttcaagcctaaactttctaggaacacctaagtgggtggcagct-3’

-910 (Human)

5’-cctactttgtgccaggttctattctaggaactaagggatacaactttgaa-3’

-1851 (Human)

5’-cagtggaagtcagtctggagtgttctcagaaaatgaaaaaatagctgggca-3’

-3196 (Murine)

5’-caaatgacttatctgatacactggccttcggagaaaagcaagtcaacacctcatt-3’

-3394 (Murine)

5’-gttgtgagccatcatgtggtttctgggaattagaattcagggcctctgc-3’

-3809 (Murine)

4.3 Potential Impact of STAT5 Regulation of Adiponectin
Prolactin release from the pituitary is pulsatile and occurs approximately every 95
minutes in men (108). Continuous PRL release is inhibited by dopamine, which signals
through the D2 receptor (D2R) on the surface of lactotrophs. Studies have shown that
D2R expression in obese animal models is lowered, and that subsequent activation of the
D2R in these models results in reduced body mass (109). Interestingly, it has been
documented that pulsatile prolactin release in obese women is elevated in proportion to
the amount of visceral fat excess (110), which may be the result of lowered dopaminergic
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inhibition of PRL release. Furthermore, plasma PRL concentrations are highest during
sleep (111), and studies have indicated that individuals with increased abdominal
circumference (an indicator of visceral fat content), experience enhanced insulin
resistance during sleep (112). Therefore, taking into account the data presented in this
thesis, it can be hypothesized that elevated PRL levels during the condition of obesity
causes a decrease in the amount of adiponectin released by adipocytes. As previously
mentioned (56), lowered levels of adiponectin over time may result in the unnatural
storage of triglyceride in muscle and liver which is a condition heavily correlated with the
development of metabolic syndrome. Thus, lowered levels of adiponectin due to the
actions of STAT5 present a possible mechanism for the development of metabolic
syndrome.
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